ITCC - Innovative Therapies for Children with Cancer in Europe

  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us


    Solid Tumor

    Phase I-II Study of Vinblastine in combination with Nilotinib in children and adolescents with refractory or recurrent low-grade glioma : A SIOP and ITCC protocol


    Solid Tumor

    A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma

  • Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with...

  • A multi-center, open-label, non-randomized, phase I dose escalation study of regorafenib (BAY 73-4506) in pediatric subjects with solid malignant tumors that are recurrent or refractory to standard...

  • Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal...

  • Phase 1/2 Study of Lenvatinib (E7080) in Children and Adolescents with Relapsed or Refractory Solid Malignancies


    Solid Tumor

    Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication : BIOMEDE

  • A phase I/II study of Azacytidine (VIDAZA®) in pediatric patients with relapsed high-grade pediatric MDS or JMML

1 - 8 sur 28
<< Premier < Précédent 1 2 3 4 Dernier >>